Results 1 to 10 of about 588 (110)
Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases
Bruton’s tyrosine kinase (BTK) plays a crucial role in B-cell receptor and Fc receptor signaling pathways. BTK is also involved in the regulation of Toll-like receptors and chemokine receptors.
Datong Zhang, He Gong, Fancui Meng
doaj +3 more sources
Targeting Solid Tumors With BTK Inhibitors [PDF]
The repurposing of FDA-approved Bruton’s tyrosine kinase (BTK) inhibitors as therapeutic agents for solid tumors may offer renewed hope for chemotherapy-resistant cancer patients.
Fatih M. Uckun, Taracad Venkatachalam
doaj +3 more sources
Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies
B cell receptor (BCR) signaling is involved in the pathogenesis of B cell malignancies. Activation of BCR signaling promotes the survival and proliferation of malignant B cells.
Danling Gu +4 more
doaj +1 more source
Bruton tyrosine kinase (BTK) is an essential enzyme in the signaling pathway of the B-cell receptor (BCR) and is vital for the growth and activation of B-cells.
Qi Zhang +3 more
doaj +1 more source
The advent of BTK inhibitors has changed the treatment of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). The first-in-class BTK inhibitor ibrutinib has shown remarkable therapeutic effects and manageable toxicities in ...
Jing Zhang +3 more
doaj +1 more source
Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors
Bruton tyrosine kinase (BTK) is involved in a multifarious inflammatory and autoimmune process. As a result, BTK has emerged as a promising novel remedial target for amalgamated autoimmune diseases.
Piyu Parth Naik
doaj +1 more source
Structure of BTK kinase domain with the second-generation inhibitors acalabrutinib and tirabrutinib.
Bruton's tyrosine kinase (BTK) is the target of the therapeutic agent, Ibrutinib, that treats chronic lymphocyte leukemia (CLL), mantle cell lymphoma (MCL) and other B cell malignancies. Ibrutinib is a first in class, covalent BTK inhibitor that limits B-
David Y Lin, Amy H Andreotti
doaj +2 more sources
Bruton's tyrosine kinase (BTK) inhibitors represent a class of drugs that have demonstrated their efficacy and safety in patients with chronic lymphocytic leukemia and non-Hodgkin's lymphomas who were considered refractory to any previously used type of ...
Yu. S. Torshina +4 more
doaj +1 more source
Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib have shown good clinical ...
Yuqin Song +18 more
doaj +1 more source
Bruton's tyrosine kinase (BTK) is a protein involved in B-cell-receptor signaling and B-cell proliferation. The pathophysiology of several autoimmune diseases, such as pemphigus disorder, relies on the BTK signaling pathway.
Yekta Ghane +4 more
doaj +1 more source

